Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Gefitinib

FDA-approved product (tablet, oral), marketed as Gefitinib, Iressa.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Gefitinib
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Neoplasm
  • Non-small cell lung carcinoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Epidermal growth factor receptor (egfr) tyrosine kinase inhibitors
FDA pharmacologic class
Kinase Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA56.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli50.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae31.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis65.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Gefitinib in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.3 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.8 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.9 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.5 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Gefitinib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer

    NCT00100945 · start 2005-07

    Registered record
    Registry ID
    NCT00100945
    Conditions
    Esophageal Cancer
    Interventions
    gefitinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2005-07
    Completion
    2009-10
    Enrolment
    70

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEsophageal Cancer
    Interventiongefitinib
    PhasePhase 2
    Registry statusCompleted

  • Study Evaluating Gefitinib (IRESSA®) in Subjects With Solid Malignancies That Are Locally Advanced, Recurrent or Metastatic

    NCT00127829 · start 2005-07

    Registered record
    Registry ID
    NCT00127829
    Conditions
    Tumors
    Interventions
    Gefitinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2005-07
    Completion
    2008-01
    Enrolment
    66

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTumors
    InterventionGefitinib
    PhasePhase 1
    Registry statusCompleted

  • A Phase I Study of Cetuximab in Combination With Gefitinib in Patients With Advanced/Metastatic Non-Small Cell Lung Cancer

    NCT00162318 · start 2005-03

    Registered record
    Registry ID
    NCT00162318
    Conditions
    Non-Small-Cell Lung Carcinoma
    Interventions
    Cetuximab + Gefitinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2005-03
    Completion
    2006-04
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-Small-Cell Lung Carcinoma
    InterventionCetuximab + Gefitinib
    PhasePhase 1
    Registry statusCompleted

  • Phase II Study of Skin Toxicity Dosing of IRESSA (Gefitinib) in Squamous Cell Carcinoma of the Head and Neck

    NCT00519077 · start 2005-03

    Registered record
    Registry ID
    NCT00519077
    Conditions
    Head and Neck Neoplasms
    Interventions
    Gefitinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2005-03
    Completion
    2013-05
    Enrolment
    44

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHead and Neck Neoplasms
    InterventionGefitinib
    PhasePhase 2
    Registry statusCompleted

  • Phase 2 Study Of Neoadjuvant Iressa Treatment In Stage 1 NSCLC

    NCT00188617 · start 2005-01

    Registered record
    Registry ID
    NCT00188617
    Conditions
    LUNG CANCER
    Interventions
    GEFITINIB
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2005-01
    Completion
    2009-11
    Enrolment
    35

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLUNG CANCER
    InterventionGEFITINIB
    PhasePhase 2
    Registry statusCompleted

  • Study of Gefitinib and Docetaxel as Salvage Therapy in Advanced Pancreatic Carcinoma

    NCT00177242 · start 2004-09

    Registered record
    Registry ID
    NCT00177242
    Conditions
    Cancer
    Interventions
    Gefitinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2004-09
    Completion
    2006-12
    Enrolment
    45

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCancer
    InterventionGefitinib
    PhasePhase 2
    Registry statusCompleted

  • Phase II Iressa Versus Vinorelbine (INVITE)

    NCT00256711 · start 2004-07

    Registered record
    Registry ID
    NCT00256711
    Conditions
    Non-Small-Cell Lung Carcinoma
    Interventions
    Gefitinib; Vinorelbine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2004-07
    Completion
    2006-02
    Enrolment
    192

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-Small-Cell Lung Carcinoma
    InterventionGefitinib; Vinorelbine
    PhasePhase 2
    Registry statusCompleted

  • A Trial to Evaluate the Combination of Iressa & Faslodex® in Patients With Advanced or Metastatic Breast Cancer

    NCT00234403 · start 2004-05

    Registered record
    Registry ID
    NCT00234403
    Conditions
    Breast Cancer
    Interventions
    gefitinib and fulvestrant
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2004-05
    Completion
    2007-10
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    Interventiongefitinib and fulvestrant
    PhasePhase 2
    Registry statusCompleted

  • A Phase I/II Study of Bexarotene in Combination With ZD1839 (IRESSA®) in the Treatment of Non-Small Cell Lung Cancer

    NCT00238628 · start 2004-04

    Registered record
    Registry ID
    NCT00238628
    Conditions
    Lung Cancer
    Interventions
    Bexarotene; Iressa
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2004-04
    Completion
    2005-12
    Enrolment
    6

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLung Cancer
    InterventionBexarotene; Iressa
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Phase II Neoadjuvant ER+/PgR + Arimidex +/- Iressa Study

    NCT00255463 · start 2004-01

    Registered record
    Registry ID
    NCT00255463
    Conditions
    Breast Cancer
    Interventions
    Anastrazole; Gefitinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2004-01
    Completion
    2005-11
    Enrolment
    185

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    InterventionAnastrazole; Gefitinib
    PhasePhase 2
    Registry statusCompleted

  • A Study Of Nasopharyngeal Carcinoma (NPC) Treated With Celecoxib And ZD1839

    NCT00212108 · start 2003-11

    Registered record
    Registry ID
    NCT00212108
    Conditions
    Nasopharyngeal Carcinoma
    Interventions
    celecoxib, gefitinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2003-11
    Completion
    2009-01
    Enrolment
    22

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNasopharyngeal Carcinoma
    Interventioncelecoxib, gefitinib
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Iressa 2nd Line Phase III Study in Japan

    NCT00252707 · start 2003-09

    Registered record
    Registry ID
    NCT00252707
    Conditions
    Non-Small Cell Lung Cancer
    Interventions
    Gefitinib or Docetaxel
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2003-09
    Completion
    2006-11
    Enrolment
    484

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-Small Cell Lung Cancer
    InterventionGefitinib or Docetaxel
    PhasePhase 3
    Registry statusCompleted

  • Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer

    NCT00068497 · start 2003-08

    Registered record
    Registry ID
    NCT00068497
    Conditions
    Anaplastic Thyroid Cancer; Insular Thyroid Cancer; Metastatic Parathyroid Cancer; Recurrent Adenoid Cystic Carcinoma of the Oral Cavity; Recurrent Basal Cell Carcinoma of the Lip; Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity; Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity; Recurrent Lymphoepithelioma of the Nasopharynx; Recurrent Lymphoepithelioma of the Oropharynx; Recurrent Metastatic Squamous Neck Cancer With Occult Primary; Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity; Recurrent Mucoepidermoid Carcinoma of the Oral Cavity; Recurrent Non-small Cell Lung Cancer; Recurrent Parathyroid Cancer; Recurrent Salivary Gland Cancer; Recurrent Squamous Cell Carcinoma of the Hypopharynx; Recurrent Squamous Cell Carcinoma of the Larynx; Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity; Recurrent Squamous Cell Carcinoma of the Nasopharynx; Recurrent Squamous Cell Carcinoma of the Oropharynx; Recurrent Squam
    Interventions
    gefitinib
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2003-08
    Completion
    Not recorded
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAnaplastic Thyroid Cancer; Insular Thyroid Cancer; Metastatic Parathyroid Cancer; Recurrent Adenoid Cystic Carcinoma of the Oral Cavity +17 more
    Interventiongefitinib
    PhaseNot applicable
    Registry statusCompleted

  • Gefitinib in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer That Did Not Respond to Iodine Therapy

    NCT00095836 · start 2003-03

    Registered record
    Registry ID
    NCT00095836
    Conditions
    Head and Neck Cancer
    Interventions
    Gefitinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2003-03
    Completion
    2011-03
    Enrolment
    27

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHead and Neck Cancer
    InterventionGefitinib
    PhasePhase 2
    Registry statusCompleted

  • Gefitinib Plus Temozolomide in Treating Patients With Malignant Primary Glioma

    NCT00027625 · start 2002-01-28

    Registered record
    Registry ID
    NCT00027625
    Conditions
    Brain and Central Nervous System Tumors
    Interventions
    gefitinib; temozolomide
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2002-01-28
    Completion
    2005-11-01
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBrain and Central Nervous System Tumors
    Interventiongefitinib; temozolomide
    PhasePhase 1
    Registry statusCompleted